Your browser doesn't support javascript.
loading
The impact of aberrant von Willebrand factor-GPIbα interaction on megakaryopoiesis and platelets in humanized type 2B von Willebrand disease model mouse.
Kanaji, Sachiko; Morodomi, Yosuke; Weiler, Hartmut; Zarpellon, Alessandro; Montgomery, Robert R; Ruggeri, Zaverio M; Kanaji, Taisuke.
Affiliation
  • Kanaji S; Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA; Blood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee. skana@scripps.edu.
  • Morodomi Y; Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla.
  • Weiler H; Blood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee.
  • Zarpellon A; Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA; MERU-VasImmune, Inc., San Diego.
  • Montgomery RR; Blood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee, WI; Children's Research Institute, Children's Hospital of Wisconsin, Milwaukee, WI; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226.
  • Ruggeri ZM; Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA; MERU-VasImmune, Inc., San Diego.
  • Kanaji T; Department of Molecular Medicine, MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA; Blood Research Institute, Blood Center of Wisconsin, Versiti, Milwaukee.
Haematologica ; 107(9): 2133-2143, 2022 09 01.
Article de En | MEDLINE | ID: mdl-35142156
ABSTRACT
Type 2B von Willebrand disease (VWD) is caused by gain-of-function mutations in von Willebrand factor (VWF). Increased VWF affinity for GPIba results in loss of high molecular weight multimers and enhanced platelet clearance, both contributing to the bleeding phenotype. Severity of the symptoms vary among type 2B VWD patients, with some developing thrombocytopenia only under stress conditions. Efforts have been made to study underlying pathophysiology for platelet abnormalities, but animal studies have been limited because of species specificity in the VWF-GPIba interaction. Here, we generated a severe form of type 2B VWD (p.V1316M) knockin mice in the context of human VWF exon 28 (encoding A1 and A2 domains) and crossed them with human GPIba transgenic strain. Heterozygous mutant mice recapitulated the phenotype of type 2B VWD in autosomal dominant manner and presented severe macrothrombocytopenia. Of note, platelets remaining in the circulation had extracytoplasmic GPIba shed-off from the cell surface. Reciprocal bone marrow transplantation determined mutant VWF produced from endothelial cells as the major cause of the platelet phenotype in type 2B VWD mice. Moreover, altered megakaryocyte maturation in the bone marrow and enhanced extramedullary megakaryopoiesis in the spleen were observed. Interestingly, injection of anti-VWF A1 blocking antibody (NMC-4) not only ameliorated platelet count and GPIba expression, but also reversed MK ploidy shift. In conclusion, we present a type 2B VWD mouse model with humanized VWF-GPIba interaction which demonstrated direct influence of aberrant VWF-GPIba binding on megakaryocytes.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Thrombopénie / Maladies de von Willebrand / Maladie de von Willebrand de type 2 Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Haematologica Année: 2022 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Thrombopénie / Maladies de von Willebrand / Maladie de von Willebrand de type 2 Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Haematologica Année: 2022 Type de document: Article